Cargando…

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair

BACKGROUND: Microglia are the resident macrophages of the central nervous system (CNS). In multiple sclerosis (MS) and related experimental models, microglia have either a pro-inflammatory or a pro-regenerative/pro-remyelinating function. Inhibition of Bruton’s tyrosine kinase (BTK), a member of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Elodie, Aigrot, Marie-Stéphane, Grenningloh, Roland, Stankoff, Bruno, Lubetzki, Catherine, Boschert, Ursula, Zalc, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2020
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685672/ https://www.ncbi.nlm.nih.gov/pubmed/33282676 http://dx.doi.org/10.3233/BPL-200100

Ejemplares similares

Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
por: Torke, Sebastian, et al.
Publicado: (2020)

Teriflunomide Promotes Oligodendroglial 8,9-Unsaturated Sterol Accumulation and CNS Remyelination
por: Martin, Elodie, et al.
Publicado: (2021)

From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases
por: Dubois-Dalcq, Monique, et al.
Publicado: (2008)

Genetically modified macrophages accelerate myelin repair
por: Aigrot, Marie‐Stéphane, et al.
Publicado: (2022)

Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies
por: Henriet, Esther, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Gray and White Matter Demyelination and Remyelination Detected with Multimodal Quantitative MRI Analysis at 11.7T in a Chronic Mouse Model of Multiple Sclerosis
por: Petiet, Alexandra, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
por: Roschewski, Mark, et al.
Publicado: (2020)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Demyelination in multiple sclerosis
por: Lubetzki, Catherine, et al.
Publicado: (2014)

Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
por: Patsatsi, Aikaterini, et al.
Publicado: (2021)

Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
por: Ng, Yen-Shing, et al.
Publicado: (2004)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
por: Weber, Alexander N. R., et al.
Publicado: (2017)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2019)

The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
por: Dispenza, Melanie C.
Publicado: (2021)

Myelin Plasticity and Repair: Neuro-Glial Choir Sets the Tuning
por: Ronzano, Remi, et al.
Publicado: (2020)

Amelioration of age‐related brain function decline by Bruton's tyrosine kinase inhibition
por: Ekpenyong‐Akiba, Akang E., et al.
Publicado: (2019)

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
por: Suresh, Ragha V., et al.
Publicado: (2023)

Live-Imaging of Myelin in Animal Models and in Human
por: Zalc, Bernard
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ja809c3g51dcelbli7jer34s0r